RISHON LE ZION, Israel, May 29, 2025 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. ("BOS" or the "Company") (NASDAQ: BOSC) reported its financial results for the first quarter of the year 2025. First Quarter 2025 Financial Highlights: Revenues increased by 33.1% to $15.0 million from $11.3 million in the first quarter of the year 2024;Gross profit margin improved to 23.9% compared to 22.7% in the first quarter of the year 2024;EBITDA increased by 86.2% to $1.9 million compared to $1.0 million in the ...

Core Viewpoint - Canadian Banc Corp. has announced its intention to initiate a Normal Course Issuer Bid (NCIB) to repurchase its Preferred Shares and Class A Shares, starting June 2, 2025, and ending June 1, 2026 [1]. Group 1: NCIB Details - The company plans to buy up to 3,742,582 Preferred Shares and 3,778,760 Class A Shares, which represents 10% of the public float of 37,425,824 Preferred Shares and 37,787,604 Class A Shares [2]. - As of May 21, 2025, there were 37,448,395 Preferred Shares and 37,821,364 Class A Shares issued and outstanding [2]. - The company will limit its purchases to a maximum of 748,967 Preferred Shares and 756,427 Class A Shares in any 30-day period, equating to 2% of the issued and outstanding shares as of May 21, 2025 [2]. Group 2: Board's Perspective - The Board of Directors, advised by Quadravest Capital Management Inc., believes that the share repurchases are in the best interests of the company and represent a desirable use of its funds [3]. - All repurchased shares will be cancelled following the NCIB [3]. Group 3: Investment Portfolio - The company invests in a portfolio of six publicly traded Canadian banks, which include Bank of Montreal, Canadian Imperial Bank of Commerce, Royal Bank of Canada, The Bank of Nova Scotia, National Bank of Canada, and The Toronto-Dominion Bank [4].

Q1 2025 highlighted the growing traction of the company’s data collection solutions with leading AI and eCommerce players worldwide Company strategically accelerated investments in scalable infrastructure and next-gen technologies to meet the rising demand for AI-ready data and to future-proof its position among top-tier global companies First quarter 2025 revenue reached $7.1 million, in line with guidance, net profit was at $0.4 million and adjusted EBITDA exceeded guidance, reaching $1.3 million Cash and ...

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Financial 15 Split Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to time, if it is ...

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit fi ...

All-Natural Line of Wellness Products Designed to Support Overall Well-Being Now Available in MassachusettsNORWOOD, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), the company behind the award-winning flower and concentrate brand, Nature’s Heritage™, continued to drive innovation with the launch of MycroDose by Nature’s Heritage, a vegan line of all-natural wellness products that combine the power of full-spectrum cannabis with the added benefits of functional mus ...

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Flow Capital Corp. (TSXV:FW) (“Flow Capital” or the “Company”) is pleased to announce the successful closing of a US$5.0 million senior note investment in Congruity 360, a leading provider of unstructured data management and risk mitigation solutions. Congruity 360’s Classify360 platform equips organizations with critical capabilities to understand, manage, and secure petabyte-scale unstructured data across cloud, SaaS, and on-premises environments. Its capabilities ...

VANCOUVER, British Columbia, May 29, 2025 (GLOBE NEWSWIRE) -- Coppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF) (“Coppernico” or the “Company”), is pleased to announce the details of its upcoming virtual Annual General Meeting of Shareholders (the "Meeting"), to be held on Tuesday, June 24, 2025, at 10:00 a.m. Pacific Time, as well as a leadership fireside chat hosted by 3L Capital (the "Webinar"), scheduled for Wednesday, June 4, 2025, at 8:00 a.m. Pacific Time. Annual General Meeting of Shareholders The Me ...

Core Viewpoint - Immunic, Inc. has announced a public offering of pre-funded warrants and series A and B warrants, aiming to raise approximately $65 million initially, with potential total gross proceeds of up to $130 million if all warrants are exercised [1][3]. Group 1: Offering Details - The public offering price for one Pre-Funded Warrant, one Series A Warrant, and one Series B Warrant is set at $0.7499 [1]. - The Pre-Funded Warrants are immediately exercisable, while Series A Warrants can be exercised until December 31, 2025, and Series B Warrants can be exercised starting October 1, 2025, for a period of five years [1]. - The offering is expected to close around June 3, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, operations, and other general corporate purposes [4]. Group 3: Company Overview - Immunic, Inc. is focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, with its lead program, vidofludimus calcium (IMU-838), currently in phase 3 trials for relapsing multiple sclerosis [7]. - Vidofludimus calcium has shown therapeutic activity in earlier trials and combines neuroprotective effects with anti-inflammatory properties [7]. - The company is also developing IMU-856 for gastrointestinal diseases and IMU-381, which is in preclinical testing [7].

Company Overview - Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases [3] - The company's lead product candidate, obexelimab, is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, aimed at inhibiting the activity of B cells involved in autoimmune diseases without depleting them [3] - Zenas aims to leverage its experienced leadership and disciplined product candidate acquisition strategy to identify and develop therapies that provide superior clinical benefits to patients [3] Upcoming Events - Zenas BioPharma will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET [1] - A live webcast and archived replay of the presentation will be available on the company's website under the "Events and Presentations" section [2]